Transition Therapeutics (TTHI)
Transition Therapeutics Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TTHI Revenues Range, Past 5 Years
| Minimum | -0.04M | Jun 2008 |
| Maximum | 29.67M | Dec 2010 |
| Average | 3.468M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these TTHI related companies
TTHI News
Transition Therapeutics Announces Third Quarter Fiscal 2012 Financial Results
May 08, 4:01PM GlobeNewswire
May 08, 4:01PM GlobeNewswire
Transition Therapeutics Announces ELND-005 Presentations at the American Academy of Neurology Meeting
Apr 26, 11:01AM GlobeNewswire
Apr 26, 11:01AM GlobeNewswire
$TTHI http://stks.co/36vD tiny #BIOTECH with nice bottom on the chart, $ELN partnership, good cash pstn - $TTHI
about 65 days ago by LTbioinvestor
about 65 days ago by LTbioinvestor
Transition Therapeutics to Present at the Cowen & Company 32nd Annual Health Care Conference
Mar 01, 10:55AM GlobeNewswire
Mar 01, 10:55AM GlobeNewswire
Transition Therapeutics, Inc. (TTHI) Reports Q2 Loss of $0.15, Had No Revenue
Feb 09, 4:38PM Street Insider
Feb 09, 4:38PM Street Insider
Transition Therapeutics Announces Second Quarter Fiscal 2012 Financial Results
Feb 09, 4:01PM GlobeNewswire
Feb 09, 4:01PM GlobeNewswire
Transition Therapeutics announces initiation of TT-401 Phase l clinical study
Dec 12, 6:39AM theflyonthewall.com
Dec 12, 6:39AM theflyonthewall.com
Transition Therapeutics announces departure of its president and CFO
Dec 11, 12:02PM theflyonthewall.com
Dec 11, 12:02PM theflyonthewall.com
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
Dec 09, 6:30PM GlobeNewswire
Dec 09, 6:30PM GlobeNewswire
Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results
Dec 01, 4:01PM GlobeNewswire
Dec 01, 4:01PM GlobeNewswire
$TTHI Insider Buy: $2.6M of stock bought by Jack Schuler on November 22, 2011 http://stks.co/1FkJ
about 191 days ago by MarketBrief
about 191 days ago by MarketBrief
Transition Therapeutics (TTHI) Reports Encouraging, But Not Siginificant, ELND005 Phase 2 Data
Sep 27, 7:15AM Street Insider
Sep 27, 7:15AM Street Insider
Transition Therapeutics Announces Fiscal 2011 Year End Financial Results
Sep 19, 4:01PM GlobeNewswire
Sep 19, 4:01PM GlobeNewswire
Transition Therapeutics to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
Sep 09, 8:01AM GlobeNewswire
Sep 09, 8:01AM GlobeNewswire
$TTHI http://chart.ly/8xpbpfy failing into downtrend resistance. Couldn't break above 4.25 for second day in a row.
about 396 days ago by mykaljohncox
about 396 days ago by mykaljohncox
$TTHI failing into downtrend resistance. Couldn't break above 4.25 for second day in a row.
about 396 days ago by mykaljohncox
about 396 days ago by mykaljohncox
Transition Therapeutics $TTHI up 13% in early trade, not clear why. Canadian dev-stage pharmaceutical firm.
about 438 days ago by MagicDiligence
about 438 days ago by MagicDiligence
Transition Therapeutics $TTHI down 12% on no available news. This dev-stage biopharm is a wild trader.
about 445 days ago by MagicDiligence
about 445 days ago by MagicDiligence
Boom! Recent MFI addition Transition Therapeutics $TTHI up 30% on strong Q2 results.
about 465 days ago by MagicDiligence
about 465 days ago by MagicDiligence
A few new MFI stocks today. Transition Therapeutics $TTHI, another dev-stage bio-pharma. These guys are lottery ticket stocks.
about 478 days ago by MagicDiligence
about 478 days ago by MagicDiligence
The beaten down biotechs are still popping. Why not $TTHI next? I'm in for a few.
about 521 days ago by britepathos
about 521 days ago by britepathos
$TTHI my analysis was correct in the end.Swift downturn had me thinking otherwise and if had played a stop it would have been 2.91.Flat g/l
about 623 days ago by Detroitblues
about 623 days ago by Detroitblues
$ELN $TTHI says topline results for phase 2 trial of ELND005 did not achieve significance; to begin phase 3 trial
about 662 days ago by Street_Insider
about 662 days ago by Street_Insider
$ELN & $TTHI say Alzheimer's drug candidate ELND005 failed ph 2 study but will move into ph 3 study anyway... sounds like $ELN's M.O.
about 662 days ago by adamfeuerstein
about 662 days ago by adamfeuerstein
$tthi volume through the roof today if this can take out this 3.60 offer can be sick runner
about 666 days ago by danshep55
about 666 days ago by danshep55
$tthi featured at http://www.newbiomedicine.com/ as a stock of the month - double whammy with ASCO if they present abstracts.
about 751 days ago by OBAMA_DA_FOOL
about 751 days ago by OBAMA_DA_FOOL
$TTHI as much as I hate these guys for screwing me before, something is going down. Any ideas ladies and gents?
about 792 days ago by Kaunteya
about 792 days ago by Kaunteya
$MDVN the latest in a long list of failed Alzheimer's drug stories. Remember Flurizan ($MYGN), Alzhamed ($NRMX), $TTHI, etc...
about 821 days ago by JayBWood
about 821 days ago by JayBWood
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TTHI | 1.95 | -0.09 | -4.41% | 52.49M |
| TTGT | 5.08 | -0.15 | -2.87% | 203.03M |
| TTF | 15.04 | -0.36 | -2.34% | |
| TTEK | 24.62 | -0.37 | -1.48% | 1.578B |
| TTEC | 14.66 | -0.24 | -1.61% | 843.64M |
| TICC | 9.37 | -0.10 | -1.06% | 351.05M |
| TIBX | 26.32 | -0.43 | -1.61% | 4.457B |
| TIBB | 12.75 | -0.59 | -4.42% | 157.46M |
| TI.A | 6.82 | +0.08 | +1.19% | |
| TI | 8.465 | +0.18 | +2.23% | 11.11B |
